Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response Study

Inclusion Criteria: * Healthy male or female participants. * Participants have suitable veins for cannulation or repeated venipuncture. * Negative SARS-CoV-2 RT-PCR or SARS-CoV-2 rapid antigen test result at Visit 1. * Body weight ≥ 45 kg and ≤ 110 kg and body mass index ≥ 18 and \<32 kg/m2 at Screening. * Able to complete the Follow-up Period up to Day 365 as required by the protocol. Exclusion Criteria: * History of any clinically important disease or disorder. * Receipt of any immunoglobulin (either COVID-19 or non-COVID related) or blood products within 6 months prior to Day 1. * Receipt of an EVUSHELD monoclonal antibody (mAb) against SARS-CoV-2 within last 15 months before Day 1. * Receipt of a COVID-19 vaccine within 14 days prior to Visit 1. * SARS-CoV-2 infection within one month prior to Visit 1 (confirmed either by laboratory testing or a rapid test \[including at-home testing\]). * Women who are pregnant, lactating, or of childbearing potential and not using a highly effective method of contraception or abstinence from at least 4 weeks prior to study intervention administration and until at least 6 months after study intervention administration. * Known or suspected congenital or acquired immunodeficiency, or receipt of immunosuppressive therapy, * Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention. This includes any acute (time-limited) or febrile (temperature ≥ 38.0°C \[100.4ºF\]) illness/infection on day prior to or day of planned dosing; participants excluded for transient acute illness may be dosed if illness resolves within the Screening Period or may be rescreened once. * Any abnormal laboratory values as described in protocol. * Any known HIV or hepatitis B or C infection at Screening. * History of alcohol or substance abuse that in the opinion of the Investigator might interfere with the trial conduct or completion. * Known hypersensitivity to AZD3152. * Previous hypersensitivity or severe adverse reaction following administration of a mAb.